Don’t miss this opportunity to connect with the Korea investor community and shape cross-board partnerships.
Korea is one of the most dynamic countries in OECD, with K-Bio advancing technology innovation and new drug development. Do you know Korea is #5 in total R&D investment and named by Bloomberg Innovation Index as #1 country among OECD?
This panel brings Korea leading investors with KIMCo (Korea Innovative Medicines Consortium) to discuss the latest investment dynamics in K- bio and more importantly to navigate what’s going to be in cross-board investment from/to Korea and Global.
We welcome investors, biotech and biopharma who would like to connect to the Korea investor community and expedite business development opportunities for the future!
WHO’S IN THE ROOM?
Korea Innovative Medicines Consortium(KIMCo) was launched as a Korean open innovation platform to accelerate collaborations for industry innovative growth. KIMCo is a non-profit organization funded by 59 Korean pharmas and KPBMA that operates with strategic partnersㅡgovernment, institutions, bioventures, VCsㅡand undertakes joint projects using combined resources and capabilities. KIMCo’s co-investment project is the core part of the organization’s initiative to develop innovative medicines. In addition, KIMCo expedites cross-board partnering for diverse and extensive collaborations. KIMCo is your gateway for collaborations.
DAYLI Partners is a healthcare-focused venture capital firm based in Seoul, Korea. The total assets under management are $300M, with over 80 portfolio companies. We invest in therapeutics, diagnostics, medical devices, and digital healthcare in North America and Asia. Our investment team consists of clinicians, researchers, healthcare analysts, and fund managers with deep industry and academic networks in the biotech and healthcare space. We are looking to invest in seed to growth stage companies, with a flexible cheque size tailored to each investment.
Yuanta Investment(YTI) is a leading venture capital and private equity firm based in Korea, as a subsidiary of Yuanta Financial Holdings. YTI raised almost 40 funds and successfully invested in more than 520 companies mainly in Korea and Asia over 34 years. Currently, YTI manages an AUM of USD 700mn and is raising a 200mn fund mainly dedicated to investing in clinical-stage biotech. YTI’s healthcare investment team invests in various stage healthcare and life science companies by integrating the agility and expertise of VC with pharmaceutical industry background and the sophistication and exquisiteness of PEF management.
Stonebridge Ventures is a prominent venture capital firm based in Seoul, Korea. Founded in 2008, we have focused on early-stage and growth-stage investment across various sectors, including in AI, data, semiconductor, mobility, life sciences and healthcare. Currently, we manage an AUM of USD 1B, with over 250 portfolio companies. For the life sciences and healthcare sectors, we primarily focus on supporting innovative companies that are developing transformative therapies, technologies, and platforms. We work closely with our portfolio companies, providing not only financial capital but also strategic guidance, operational expertise and access to a network of industry leaders.